Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults Post author:Sam Post published:June 15, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Calithera Biosciences Appoints To Board Of Directors September 21, 2017 Dermira’s Acne Medication Olumacostat Glaseretil Tanks in Two Phase III Trials March 4, 2018 Illumina Accelerator in the Bay Area Makes Room for 5 New Biotech Startups July 27, 2017